Welcome to our dedicated page for Nature’S Sun SEC filings (Ticker: NATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want the essentials of Nature’s Sunshine’s direct-selling herbal-supplement business without scrolling through EDGAR? This page gathers every disclosure the company files—whether the next Nature's Sunshine quarterly earnings report 10-Q filing or a sudden 8-K—and puts them in one place. Investors who search phrases like “Nature's Sunshine SEC filings explained simply” or “Nature's Sunshine insider trading Form 4 transactions” find clear answers here. Stock Titan’s AI-powered summaries translate dense language so you spend minutes, not hours, decoding PDFs.
Use intuitive filters to locate the document you need, then let our platform do the reading. Curious whether executives are buying shares? Track Nature's Sunshine Form 4 insider transactions real-time and receive alerts on every Nature's Sunshine executive stock transactions Form 4. Building a model? Each filing comes with an AI brief—your shortcut to Nature's Sunshine earnings report filing analysis that flags segment sales trends, currency swings, and distributor count shifts. When you need the big picture, our digest of the Nature's Sunshine annual report 10-K simplified highlights sourcing risks and product-margin dynamics.
- 10-Q: revenue momentum, inventory levels, and geographic mix
- 10-K: strategic risks around raw-herb sourcing
- 8-K: supply-chain disruptions & leadership updates—Nature's Sunshine 8-K material events explained
- DEF 14A proxy: Nature's Sunshine proxy statement executive compensation comparisons
Because global distributors fuel growth, small regulatory changes can ripple through results. Stock Titan’s expert insights make understanding Nature's Sunshine SEC documents with AI straightforward. Real-time filing alerts combine with historical context so you know when new markets open, pricing shifts hit margins, or management’s pay aligns with performance—all in one continuously updated hub.
Nature's Sunshine Products (Nasdaq:NATR) filed an 8-K announcing a secondary public offering of 2,854,607 shares by major holder Fosun Pharma USA at $12.00 per share (≈$34.3 million to the seller). The company will not receive proceeds but may repurchase up to $15 million of these shares under its existing authorization, with any bought stock cancelled. Closing is slated for 27 June 2025; a 90-day lock-up applies to insiders and the selling stockholder. The underwriting agreement with D.A. Davidson & Co. carries standard terms and indemnities, and any buyback would be funded with cash and the credit facility.
Nature’s Sunshine Products, Inc. (Nasdaq: NATR) has filed a 424(b)(5) prospectus supplement covering the resale of 2,854,607 existing shares of common stock owned by the sole selling stockholder, Fosun Pharma USA Inc. The shares will be offered to the public at $12.00 per share, a 20.5 % discount to the last reported Nasdaq price of $15.10 on 24 June 2025.
The transaction is a secondary offering; therefore NATR will not receive any of the estimated $32.7 million in net proceeds (after $1.54 million in underwriting discounts) that will go directly to the selling stockholder.
Share-repurchase overlay. Under a previously announced authorization, the company has the option—but not the obligation—to repurchase up to $15 million of the offered shares at the public offering price through the underwriter, D.A. Davidson & Co. Management expects any buy-back to be funded with cash on hand and draws on its credit facility. The filing emphasizes that no minimum quantity is guaranteed, so there is no assurance the company will purchase any shares.
Key terms
- Offering size: 2,854,607 shares
- Public offering price: $12.00 per share
- Gross proceeds to selling stockholder: $34,255,284
- Underwriting discount: $0.54 per share (total $1,541,488)
- Net proceeds to selling stockholder (before expenses): $32,713,796
- Expected settlement: on or about 27 June 2025 via DTC book-entry
Strategic context. The filing does not involve the issuance of new shares, so there is no dilution to existing shareholders. However, the discounted pricing and block size could create near-term market supply pressure. Management’s discretionary buy-back authority may partially offset this pressure and signals confidence, but the lack of a binding commitment leaves uncertainty.
Form 144 Notice of Proposed Sale filed for Nature's Sunshine Products (NASDAQ: NATR) indicates a planned sale of 2,000 common shares with an aggregate market value of $29,801.88. The securities were acquired on May 2, 2025, through restricted share grants and compensation.
The filing reveals significant recent selling activity by Richard D Moss and the Richard D Moss Revocable Trust over the past 3 months, totaling 37,734 shares sold between May 9, 2025, and June 23, 2025, with gross proceeds of approximately $545,500. Notable transactions include:
- Largest single sale: 10,000 shares on May 9, 2025 ($137,426.61)
- Most recent sale: 3,000 shares on June 23, 2025 ($44,155.45)
- Average sale price: approximately $14.46 per share
The proposed sale will be executed through Wells Fargo Clearing Services, with an approximate sale date of June 25, 2025. The company currently has 18,350,801 shares outstanding.
FAQ
What is the current stock price of Nature’S Sun (NATR)?
What is the market cap of Nature’S Sun (NATR)?
What is Nature's Sunshine's core business?
How does the company ensure the quality of its products?
What products are included in Nature's Sunshine's portfolio?
How does the direct selling model benefit consumers?
In which markets does Nature's Sunshine operate?
What differentiates Nature's Sunshine from its competitors?
How does Nature's Sunshine maintain consumer trust?
What role do distributors play in the company's business model?
